

Review of: "Comparative analysis between Polymerized Type I Collagen (Fibroquel) and Baricitinib as a potential treatment for moderate-severe COVID-19 in outpatients and inpatients"

Aytenew Atnaf

Potential competing interests: No potential competing interests to declare.

Comparative analysis between Polymerized Type I Collagen (Fibroquel) and Baricitinib as a potential treatment for moderate-severe COVID-19 in outpatients and inpatients

First of all, I would like to acknowledge the Editors and Peer Reviewer team of Qeios Journal for inviting me to review this article. I have written comments as follows.

Reviewer comments:

I am very interested in the title of this research and it is current issue for clinical intervention of COVID-19. I admire the authors for their unreserved efforts to show us the best possible treatment options in their research. However, I have some minor comments for improvement of the paper so that readers can easily understand your work.

Abstract

In the Abstract part, the objective of the study is not mentioned. So, it will be better if you have shown the objective of conducting this research.

1. **Methods:** The method part is vague.

Make it materials and methods similar to the body part of your manuscript

You used Comparative, descriptive, and retrospective analysis. But what type of retrospective? Is it retrospective cross-sectional or retrospective cohort? Not clear

How many population (sample size) were enrolled in the study?

What type of statistical software were used to analyze data?

What statistical tests were used to determine the degree of association?

2. **Results:** are narrated carefully. You have stated that the adverse effects of using Baricitinib was bacterial pneumonia reported in 5 patients.

But how did you know that the pneumonia was bacterial or viral (SARS-COV2)?

By what mechanism bacterial pneumonia occur? You have to elaborate the possible mechanism of action of Baricitinib.

For further information, you can use Favalli EG et al. 2020 Baricitinib for COVID-19: a suitable treatment? Available at [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(20\)30262-0/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30262-0/fulltext)

How did you compare the effect of two drugs given that the route of administration, the dosage form and the duration of the drug is different from each other?

3. Conclusion: The conclusion is very good. I have no comments here.

Main Body of the research

1. Introduction

The introduction part is written in understandable manner and it touches critical elements of the manuscript. Therefore, I have additional idea here.

Paragraph 1 sentence 4, make "Very" to small case "very"

2. Materials and Methods

What were your study population? What two population of adult patients mean? Elaborate it.

What did you do for patients who had lost to follow up?

How did you select your study participants?

Did you use any exclusion criteria? If you say "yes", please narrate it in this section.

Why did you use Chi-square instead of odds-ratio for measurement of association? You know Chi-square cannot tell us the degree of association?

3. Results: The results should be discussed with other researches. Here, there is no discussion part, it is omitted.

4. Conclusion: I have no comments.

5. References:

Your references are very few in number. So, if possible try to add more references for discussion.